In the last decade, the endocrine-gland-derived vascular endothelial growth factor (EG-VEGF), also called prokineticin 1 (PROK1), emerged as a specific placental angiogenic factor that controls numerous aspects of normal and pathological placental angiogenesis, such as recurrent pregnancy loss (RPL), gestational trophoblastic diseases (GTD), FGR and PE. This evidence concerns the gene PROK1 and gestational trophoblastic neoplasm.